Global Journal of Cancer Therapy
Review Article
Genetic Polymorphisms and Cisplatin- Related Nephrotoxicity
Abstract: Cisplatin is one of the most widely applied
antineoplastic agents used to treat different types of solid tumours.
However, its use is limited by serious side- effects including
nephrotoxicity. Cisplatin accumulates in proximal tubule and forms
nephrotoxins that causes proximal cell injury and thereby leads to
nephrotoxicity. Cisplatin enters these proximal cells by organic
transporter molecules (OCT). Genetic polymorphism of these molecules and
other membrane transport proteins that regulate cisplatin accumulation
may influence cisplatin- related nephrotoxic outcome. Variations of DNA
repair enzymes, e.g., ERCC1, eIF3, MMS 19L, and metabolic enzymes
involved in platinum detoxification, e.g., GSTT1, GSTM1 may also have
important role in the generation of nephrotoxicity. Polymorphisms of
these genes can be used as predictive tools for such adverse- events in
an individual. Thus chemotherapy can be modulated accordingly without
compromising with antineoplastic activities of cisplatin.
http://www.peertechz.com/Cancer-Therapy/GJCT-1-101.php
Comments
Post a Comment